ERK signalling eliminates Nanog and maintains Oct4 to drive the formative pluripotency transition
Development · 15.07.2024 · 151 (14)
DOI: 10.1242/dev.203106 ↗Kurz gefasst
Fachartikel in der Zeitschrift Development, online erschienen am 26.07.2024. Verfasst von Carla Mulas und 6 weiteren Autor:innen. Beteiligte Einrichtung: Wellcome Trust - Medical Research Council Stem Cell Institute, University of Cambridge, Cambridge CB2 0AW, UK. Hauptthemen laut MEDLINE: Nanog Homeobox Protein, Octamer Transcription Factor-3, Pluripotent Stem Cells, MAP Kinase Signaling System. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: King's College London, Company of Biologists, Medical Research Council.
Abstract (Originalsprache)
Naïve epiblast cells in the embryo and pluripotent stem cells in vitro undergo developmental progression to a formative state competent for lineage specification. During this transition, transcription factors and chromatin are rewired to encode new functional features. Here, we examine the role of mitogen-activated protein kinase (ERK1/2) signalling in pluripotent state transition. We show that a primary consequence of ERK activation in mouse embryonic stem cells is elimination of Nanog, which precipitates breakdown of the naïve state gene regulatory network. Variability in pERK dynamics results in heterogeneous loss of Nanog and metachronous state transition. Knockdown of Nanog allows exit without ERK activation. However, transition to formative pluripotency does not proceed and cells collapse to an indeterminate identity. This outcome is due to failure to maintain expression of the central pluripotency factor Oct4. Thus, during formative transition ERK signalling both dismantles the naïve state and preserves pluripotency. These results illustrate how a single signalling pathway can both initiate and secure transition between cell states.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Wellcome Trust - Medical Research Council Stem Cell Institute, University of Cambridge, Cambridge CB2 0AW, UK.
- Randall Centre for Cell and Molecular Biology, King's College London, London SE1 1YR, UK.
- Altos Labs Cambridge Institute of Science, Granta Park, Cambridge CB21 6GP, UK.
- Institute of Cell Biology and Neuroscience, Goethe University, Frankfurt 60439, Germany.
- Institute of Bioengineering, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne CH-1015, Switzerland.
- Living Systems Institute, University of Exeter, Exeter EX4 4QD, UK.
ORCID-Profile: Carla Mulas, Siiri I Salomaa, Constanze Heinzen, David M Suter, Austin Smith, Kevin J Chalut
Förderung
- King's College London
- Company of Biologists
- Medical Research Council
- Leverhulme Trust
- European Research Council
- Wellcome
Zitieren
APA
Mulas, C., Stammers, M., Salomaa, S. I., Heinzen, C., Suter, D. M., Smith, A., & Chalut, K. J. (2024). ERK signalling eliminates Nanog and maintains Oct4 to drive the formative pluripotency transition. Development, 151(14). https://doi.org/10.1242/dev.203106
Vancouver
Mulas C, Stammers M, Salomaa SI, Heinzen C, Suter DM, Smith A, et al. ERK signalling eliminates Nanog and maintains Oct4 to drive the formative pluripotency transition. Development. 2024;151(14). doi:10.1242/dev.203106
BibTeX
@article{Mulas2024,
author = {Mulas, Carla and Stammers, Melanie and Salomaa, Siiri I and Heinzen, Constanze and Suter, David M and Smith, Austin and Chalut, Kevin J},
title = {ERK signalling eliminates Nanog and maintains Oct4 to drive the formative pluripotency transition},
journal = {Development},
year = {2024},
volume = {151},
number = {14},
doi = {10.1242/dev.203106}
}
EUVIMED